HER2-positive BiliaryTractCancer, zanidatamab produced sustained, meaningful clinical responses and extended survival compared to prior standards.

In patients with immunohistochemistry (IHC) 3+ tumors, response rates and overall survival were notably higher than those with IHC 2+ tumors, substantiating the use of reflex IHC testing to identify candidates for HER2-targeted therapy.

Safety remained consistent over 33 months of follow-up, and the ongoing HERIZON-BTC-302 phase 3 trial is assessing zanidatamab alongside first-line standard care in this setting.

This is a 404 error, which means you’ve clicked on a bad link or entered an invalid URL. Maybe what you are looking for can be found at Bitly.com. P.S. Bitly links are case sensitive.